Compact System Uses CMOS Digital Imaging and Is Compatible with Chemiluminescence and Fluorescence Detection and Stain-Free Technology

HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of the ChemiDoc™ Go Imaging System, the latest addition to its portfolio of ChemiDoc Imaging Systems. The system offers rapid, reliable, and highly sensitive gel and western blot imaging on a benchtop scale. 

The ChemiDoc Go Imaging System uses complementary metal oxide semiconductor (CMOS) digital imaging to capture gel and western blot images with the same high sensitivity as larger instruments. The compact, user-friendly imager supports advanced chemiluminescence as well as fluorescence detection using StarBright™ Dyes, and its three sample trays provide the versatility with a wide range of applications, including nucleic acid and protein quantitation through various detection methods. Additionally, all-LED illumination significantly improves the durability of the instrument and minimizes illumination maintenance, ensuring reliable performance over time. 

Data in western blot experiments are traditionally normalized with housekeeping proteins, which requires additional probing and stripping with multiple antibodies simultaneously in a time- and cost-intensive protocol. With the ChemiDoc Go Imaging System, users benefit from the option to use Stain-Free Imaging technology for total protein normalization, which simplifies the western blot workflow and provides quality control validation at each stage. The ChemiDoc Go Imaging System is also compatible with BR.io, Bio-Rad’s cloud-based platform for image storage and enhanced data accessibility. 

“We are excited to introduce the ChemiDoc Go Imaging System, the first benchtop imager on the market to leverage advanced CMOS digital imaging. Bio-Rad’s new imager enables researchers to capture western blot and gel images from their benchtop with high sensitivity and unparalleled versatility,” said Kenneth Oh, Global Marketing Manager at Bio-Rad Laboratories. “This latest addition to our portfolio of ChemiDoc Imaging Systems offers class-leading sensitivity, all-LED illumination, and cloud connectivity, all within a small footprint.”  

To learn more about the ChemiDoc Go Imaging System, please visit bio-rad.com/ChemiDocGo.

CHEMIDOC, STARBRIGHT, and BIO-RAD are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.  

About Bio-Rad  

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 8,000 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

Forward-Looking Statements

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.